ARTICLE | Company News
Bayer sales and marketing update
March 28, 2016 7:00 AM UTC
Germany’s Institute for Quality and Efficiency in Health Care (IQWiG) issued an addendum to a second dossier assessment for Stivarga regorafenib from Bayer saying that the drug’s benefit “is no longe...